Additionally, highly specific antinuclear antibodies (ANA) for PBC, such as Sp100 and gp210 autoantibodies, can also aid in the diagnosis of PBC, especially in AMA-negative patients.[5] In particular, the presence of anti-gp210 antibodies may be associated with disease progression in PBC patients.[6] However, AMA titers are not typically reported to correlate with progression in patients with PBC.[7] Nevertheless, accumulating evidence suggests that AMA titers may be associated with the outcome of PBC patients.[8–10]. This evidence concerns the gene BTG3 and primary biliary cholangitis.